Tildrakizumab-asm bulk supplier for pharma manufacturers

Tildrakizumab-Asm 100 mg/mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 100 mg/mL

Reference Brands: Ilumya (USA), Ilumetri (EUUK)

Tildrakizumab-asmn is a humanized IgG1/k monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). By blocking IL-23 signaling, it reduces inflammation and helps clear plaques in moderate to severe plaque psoriasis. It is prescribed for adults who need systemic therapy or phototherapy. The dosing schedule includes injections at week 0, week 4, and every 12 weeks thereafter. It is administered as a subcutaneous injection under medical supervision.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Tildrakizumab-Asm — third party manufacturing & bulk supply

Tildrakizumab-Asm 100 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Tildrakizumab-Asm is supplied as injection (prefilled syringe) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Tildrakizumab-Asm listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Tildrakizumab-Asm →

Back to Listing

Frequently Asked Questions

Tildrakizumab-asm is used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It helps reduce inflammation, skin plaques, redness, and thickness by targeting specific immune pathways involved in psoriasis.

Tildrakizumab-asm is made from the active ingredient tildrakizumab-asm, a humanized monoclonal antibody that selectively blocks interleukin-23 (IL-23), along with standard excipients used in biologic injectable formulations.

The trade name for tildrakizumab-asm is Ilumya (in the USA) and Ilumetri (in the EU and other regions).

Tildrakizumab-asm is manufactured and marketed by Sun Pharma in the USA, EU, UK, and other approved global markets.

The generic name is tildrakizumab-asm.

The brand names are Ilumya and Ilumetri, depending on the country.

It is manufactured in approved biologics manufacturing facilities in the USA and Europe, as well as other globally regulated regions authorized for monoclonal antibody production.